Charcot-Leyden crystal protein/Gal-10, abundantly expressed in eosinophils and basophils, is related to several immune diseases. Recently, crystallographic and biochemical studies showed that Gal-10 cannot bind lactose, because a glutamate residue (Glu33) from another monomer blocks the binding site. Moreover, Gal-10 actually forms a novel dimeric structure compared to other galectins. To investigate the role that Glu33 plays in inhibiting lactose binding, we mutated this residue to glutamine, aspartate, and alanine. The structure of E33A shows that Gal-10 can now bind lactose. In the hemagglutination assay, lactose could inhibit E33A from inducing chicken erythrocyte agglutination. Furthermore, we identified a tryptophan residue (Trp127) at the interface of homodimer that is crucial for Gal-10 dimerization. The variant W127A, which exists as a monomer, exhibited higher hemagglutination activity than wild type Gal-10. The solid phase assay also showed that W127A could bind to lactose-modified sepharose-6B, whereas wild type Gal-10 could not. This indicates that the open carbohydrate-binding site of the W127A monomer can bind to lactose. In addition, the distribution of EGFP-tagged Gal-10 and its variants in HeLa cells was investigated. Because Trp72 is the highly conserved in the ligand binding sites of galectins, we used EGFP-tagged W72A to show that Gal-10 could not be transported into the nucleus, indicating that Trp72 is crucial for Gal-10 transport into that organelle.
Introduction
In 19th century, Jean-Martin Charcot and Ernst Viktor von Leyden discovered Charcot-Leyden crystals (CLCs) in spleen-rich eosinophils and in the sputum of patients with bronchial asthma, respectively (Charcot and Robin 1853; Leyden 1872; Gleich et al. 1976; Ackerman et al. 1982) . CLCs are hexagonal and bipyramidal crystals (Charcot and Robin 1853; Leyden 1872) and are involved in several immune diseases, such as asthma, acute myeloid leukemia, mastocytoma (Lao et al. 1998) ; allergic rhinitis (Bryborn et al. 2010) ; celiac disease (De Re et al. 2009 ); eosinophilic cystitis (Staribratova et al. 2010) . On the genetic level, the intron-extron structure of the CLC gene is analogous to that of other galectins, with the CRD encoded by a single exon (Dyer et al.1997) . The primary sequence of CLC protein is highly conserved to the other galectins (Leffler et al. 1989; Ackerman et al. 1993; Barondes et al. 1994) . The 3-D structure of CLC protein (Leonidas et al. 1995) shows that it has a CRD like structure. Therefore, CLC protein was termed galectin-10 (Gal-10) (Leffler et al. 2002) . However, previous results showed that Gal-10 could not bind the β-galactoside lactose (Dvorak et al. 1991; Savage et al. 1997; . Careful analysis of the Gal-10 homodimer structure shows that Glu33 from one monomer may block lactose binding to the sugar binding site of another monomer. While, this hypothesis has remained unvalidated.
The mRNA of Gal-10 is highly transcribed in bone marrow (Than et al. 2014) , indicating that Gal-10 may play a key role in lymph cell maturation. In eosinophils, Gal-10 is the second most abundant protein, comprising about 10% of all proteins present (Leonidas et al.1995) . In basophils, Gal-10 is also broadly distributed (Ackerman et al. 1982 ). Macrophages do not express Gal-10, but can acquire the lectin by endocytosis (Dvorak et al. 1991) . Gal-10 spontaneously could form crystals in eosinophils, basophils and phagosomes of macrophages (Dvorak et al. 1990 ). Gal-10 has been reported to be a novel biomarker essential for anergy and suppressive function of human CD4 + CD25 + regulatory T cells (Kubach et al. 2007 ). Recently, it was found that regulatory eosinophils can suppress T cells partly through Gal-10 (Lingblom et al. 2017) . Moreover, the distribution of soluble Gal-10 and crystallized Gal-10 in cells has been investigated by transmission electron microscopy (Dvorak et al. 1988; Dvorak and Ackerman 1989) and immunofluorescence (Ackerman et al. 1982; Calafat et al. 1997; Lingblom et al. 2017) , as well as by high resolution cellular staining (Lao et al. 1998; Manny and Ellis 2012) . So far, 14 human galectins have been reported in the human genome (Liu and Rabinovich 2005; Yang et al. 2008; Than et al. 2009; Johannes et al. 2018) . Gal-1, -2, -7, -10, -13, -14, -16 and -17 that belong to the prototype category, should form dimers (Kasai and Hirabayashi 1996; Cooper 2002; Tasumi and Vasta 2007; Yang et al. 2008) . Recently, however, we used crystallography and gel filtration to show that Gal-10 (Su, Gao et al. 2018) and Gal-13 ) form novel dimeric structures that are different from those of Gal-1 (Lopez-Lucendo et al. 2004) , Gal-2 and Gal-7 (Leonidas et al. 1998) . Gal-10 forms dimers via non-covalent interactions among amino acid residues located at the CRD S-face, whereas Gal-13 forms dimers by formation of two disulfide bonds formed between Cys136 and Cys138 at their C-termini. Cys2 and Val5 are crucial for Gal-1 dimerzation (Dias-Baruffi et al. 2003) , and the Gal-1 monomer variant with two mutation sites (C2S/V5D) shows lower sugar binding affinity compared to the wild type lectin (Camby et al. 2006) . However, the key residues that promote Gal-10 dimerization remain unknown.
In the present study, we solved the crystal structures of several Gal-10 variants to assess effects on lactose binding (variants E33A, E33D, E33Q) and dimerization (variants W127A and Y35A). The structure of E33A demonstrates that this variant co-crystallizes with lactose, indicating that it recovered the ability to bind lactose. Gel filtration was performed to study the multimeric forms of these Gal-10 variants. Moreover, the hemagglutination and solid phase assays were used to investigate lectin activity and lactose binding. Finally, the distribution of EGFP-tagged fusion proteins in HeLa cells was investigated.
Results

Crystal structures of Gal-10 variants
Structural statistics for all variants are provided in Table I . Differences in Cα RMSD values compared to those reported for other Gal-10 structures (Leonidas et al. 1995; Swaminathan et al. 1999; Ackerman et al. 2002; ) are less than 0.6 Å, indicating that these structures are all similar to each other and that site-directed mutagenesis did not influence their monomeric structures. Trp127 is a key residue for Gal-10 homodimerization (see the section "Trp127 is key to Gal-10 dimerization"). Although W127A exists as monomer, the crystallization pattern of this variant was the same as wild type Gal-10. The space group and unit cell parameters are similar as with wild type Gal-10, and the monomeric structure of W127A could be merged perfectly with that of the wild type protein (Figure 1 ).
Gal-10 E33A recovers the ability to bind lactose Recently, we speculated that Gal-10 inability to bind lactose was due to Glu33 from one monomer inhibiting ligand binding to the other . Here, we mutated Glu33 to alanine, aspartate and glutamine and crystallized all variants in the presence and absence of 10 mM lactose. Electron density for lactose was only observed in the structure of E33A (Supplementary Figure 1) , such that we could refine a lactose molecule in the ligand binding site of that variant (Figure 2A ). The electron density for the glucose residue in lactose is weaker than that from galactose ( Supplementary  Figure 1) , indicating that the glucose residue is not stabilized and appears to be more flexible than galactose.
In the structure of wild type Gal-10 ( Figure 2B ), Glu33 from one monomer subunit occupies a relatively large space in the ligand binding site of another subunit . In E33A, the shorter alanine side chain could not reach into the opposing ligand binding site ( Figure 2C ). The distance between the carbon atom of the methyl group of Ala33 and O2 of lactose is 4.19 Å, which is much longer than the distance (1.62 Å) between the oxygen atom of carboxyl group of Glu33 and O2 of lactose. Therefore, the ligand binding site of E33A is more open that it could bind lactose. In contrast, mutation from glutamate to glutamine did not allow recovery of lactose binding, probably because it is about the same size as glutamate. And although aspartate has a shorter side chain than glutamate, E33D also did not permit binding of lactose to the second subunit ( Figure 2B ). The structures of W127A and Y35A also could not be co-crystallized with lactose.
The E33A ligand binding site
In a previous report, Gal-10 crystals were soaked in solution containing 0.1 M mannose for 2 days, and finally co-crystalized (Swaminathan et al. 1999) . Mannose adopts a different conformation in the ligand binding site of Gal-10 compared to lactoses in structures of other galectins, such as Gal-1, -3 and -8 (Seetharaman et al. 1998; Lopez-Lucendo et al. 2004; Ideo et al. 2011) . Comparing these structures, we found that the positions of O1' and O6' from mannose is similar to those of O6 and O4 from lactose ( Figure 3 ). These two hydroxyl groups could make two hydrogen bonds with His53 and Asn65 to stabilize the sugar binding. Trp72 could set up CH-π interactions with mannose and the galatose residue. Mannose O1' is close to lactose O6. However, the distance between O1' and O4' of mannose is shorter than O6 to O2 of lactose, indicating that the position of mannose O4' is lower than lactose O2. This may explain why mannose binding was not inhibited by Glu33.
We also compared the ligand binding sites of E33A to Gal-3 CRD (PDB: 4R9C, Su et al. 2015) and Gal-8N CRD (PDB: 5GZD, (Figure 4A ). Lactose in the ligand binding sites of Gal-3 and Gal-8 could perfectly merge with each other. In contrast, lactose in Gal-10 adopts a different conformation compared to lactose in Gal-3 and Gal-8N CRDs. In addition, this overlay also shows that Glu33 from another Gal-10 monomer almost contacts with O2 of lactose molecules in Gal-3 and Gal-8. This again implies that lactose binding to wild type Gal-10 is energetically unfavorable.
Although O3, O4 and O6 maintained similar positions as the corresponding oxygen atoms in lactose of Gal-3 and Gal-8N CRDs, the position of lactose was shifted from the canonical ligand binding site ( Figure 4A ,B). In Gal-10, Trp72 was also shifted compared to this residue in Gal-3 and Gal-8N CRDs ( Figure 4B ). On the other side of lactose, Gal-10 Cys57 is located at the same position as Arg162 in Gal-3 and Arg69 in Gal-8 (Seetharaman et al. 1998; Ideo et al. 2011 ). Arg69 in Gal-8 is a key residue for ligand binding (Ideo et al. 2011; ) and mutation of this residue would abolish the biological activity of Gal-8 (Stowell et al. 2008) . Actually, this conserved arginine residue is present in almost all identified human galectins (Gal-1, -2, -3, -4, -7, -8,-9 and -12) ).
In addition, under the pyranose ring of glucose residue, there is a conserved glutamate residue (Glu184 of Gal-3 and Glu89 of Gal-8) which could stabilize the glucose pyranose ring through hydrogen bonds in Gal-3 and Gal-8 (Seetharaman et al. 1998; Ideo et al. 2011) . However, at the same position in Gal-10, this glutamate residue is substituted by a glutamine (Gln75), whose structural characteristics are different from glutamate. Therefore, Gln75 might not stabilize the glucose residue of lactose in the Gal-10 ligand binding site like glutamate residues in Gal-3 and Gal-8 do.
Overall, the two mutation sites in the Gal-10 ligand binding site may promote lactose binding in E33A which has about a 45 degree turn compared to lactose in Gal-3 and Gal-8N CRDs. The incomfortable conformation of lactose in the ligand binding site indicates that binding between lactose and E33A is likely weaker.
In Gal-10, Arg60 from one subunit is also close to the ligand binding site of the other, and this residue has variable conformations in different structures (Supplementary Figure 2) . In wild type Gal-10, the electron density of Arg60 is absent, indicating that this residue is probably flexible ). However, the electron density of Arg60 in E33A, E33D and Y35A is apparent upon structural refinement. In E33A, Arg60 could play a role in stabilizing ligand binding by making a weak hydrogen bond with O2 of lactose ( Figure 4C ). In E33D and Y35A, the side chain of Arg60 could also be refined, albeit with a different conformation from that in E33A. In E33D, Arg60 is close to the ligand binding site, such that it might influence ligand binding. The Arg60 side chain in Y35A points in another direction compared to Arg60 in E33A (Supplementary Figure 2) .
Trp127 is key to Gal-10 dimerization
By using PISA, we previously predicted that part of the S-face contributed to formation of the Gal-10 dimer interface. Here, we found two Tyr35 residues at Gal-10 interface form a π-π interaction that might be important for dimerization of the lectin. Trp127 is fully buried in the interface region and may also be important for dimerization via its bulky aromatic side chain ). However, PISA did not show that Trp127 made any obvious hydrogen bonds or ionic interactions with other amino acid residues. Subsequently, we mutated these two residues to alanine ( Figure 5A ), and estimated the multimeric states of Gal-10 variants by using size exclusion chromatography ( Figure 5B and Supplementary Figure 3) . For wild type Gal-10, we observed one elution peak at 12.2 mL (calculated to be 25.5 kDa), consistent with previous results (Gal-10). The elution peak of Y35A was found at 12.3 mL (Supplementary Figure 3) , indicating that this variant remains dimeric, as Tyr35 is not crucial to Gal-10 dimerization. Surprisingly, the elution peak of W127A was observed at 13.8 mL (calculated to be 13.1 kDa), indicating that this variant becomes monomeric in solution ( Figure 5C ). However, the crystal parameters of W127A were similar to those of the wild type lectin ( Table I ), suggesting that the crystallization conditions forced W127A to crystallize in the same fashion.
Functional activity of Gal-10 variants
Here, we used the hemagglutination assay to investigate the biological activity of Gal-10 variants. First of all, the minimum agglutination concentrations (MAC) of Gal-10 variants for inducing chicken erythrocyte agglutination were determined ( Figure 6A ). Wild type Gal-10 induced agglutination with a MAC of 3.1 μg/mL, as previously reported . MAC values of E33A, E33D, E33Q and Y35A are 3.1, 3.1, 1.6, 6.2 μg/mL, respectively, which are not significantly different from the MAC value of wild type Gal-10. This indicates that these variants have similar activities to induce hemagglutination as wild type Gal-10. However, the MAC value of W127A is only 0.4 μg/mL, which is significantly lower than that of wild type Gal-10. This means that W127A exhibits a greater hemagglutination activity than wild type Gal-10. Lactose was used to inhibit the hemagglutination induced by Gal-10 variants ( Figure 6B ). Similar to wild type Gal-10, its variants E33D, E33Q, W127A, Y35A are not sensitive to lactose inhibition. Swaminathan et al. 1999) . The overlay shows the positions of lactose O4 and O6 are similar to mannose O6' and O1'. The distance between mannose O1' and O4' is shorter than the distance between lactose O2 and O6. This might be the reason that Glu33 could not affect wild type galectin-10 binding mannose but can influence wild type galectin-10 interacting with lactose.
However, 200 mM lactose could inhibit E33A-mediated hemagglutination. This is consistent with our crystallographic studies that demonstrate that this variant could co-crystallize with lactose. As a control, sucrose could not inhibit hemagglutination with any Gal-10 variant ( Figure 6C) .
We also used a solid phase assay to study whether Gal-10 variants could directly bind to the lactose-modified sepharose-6B ( Figure 7) . As a positive control, Gal-8_1-186 could effectively bind to the agarose beads, whereas wild type Gal-10 could not bind. This finding is consistent with previously published reports (Dvorak et al. 1991; Savage et al. 1997; . Four Gal-10 variants (E33A, E33D, E33Q and Y35A) also could not bind to the beads. Because W127A could bind to lactosemodified sepharose-6B, albeit weakly, monomeric W127A does have a functional ligand binding site that can bind lactose.
Distribution of EGFP tagged Gal-10 and the variants in HeLa cells
To assess the distribution of Gal-10 within the cell, we produced EGFP C-terminal tagged Gal-10. Based on our crystallographic results, placing the tag at the C-terminus should not perturb the dimer structure. Following transfection, we found EGFP-tagged wild type Gal-10 and seven variants (E33A, E33D, E33Q, Y35A, H53A, N65A and W127A) distributed in the nucleus and cytoplasm, consistent with a previous report (Dvorak et al.1991) . In the nucleus, several Gal-10 variants (E33D, E33Q, Y35A and W127A) were extensively distributed in the euchromatin, but not in the heterochromatin (Figure 8, Supplementary  Figure 4) . The fluoresence of EGPF in the euchromatin was light compared to other areas in these cells. However, other Gal-10 variants (WT, E33A, H53A and N65A) were equally distributed within the nucleus, indicating that Gal-10 may be in dynamic exchange in the nucleus. Interestingly, EGFP-tagged W72A was not found in the nucleus and was only distributed within the cytoplasm, either forming aggregates or entering granules ( Figure 8H, Supplementary Figure 4H ).
Discussion
Previously, we used crystallographic and biochemical methods to show that Gal-10 does not bind lactose. Even though our crystallization conditions contained 50 mM lactose, we still could not find any electron density for lactose in the ligand binding site . Swaminathan also tried to use two days to soak lactose into the ligand binding site, but this approach also failed (Swaminathan et al. 1999) . Consistent with this observation, we also found that lactose had no apparent effect in Gal-10-mediated hemagglutination. In addition, Dvorak and Savage proved that Gal-10 only artificially bind to the matrix of solid-phase assays, but not to lactose (Dvorak et al. 1991; Savage et al. 1997 ). We could explain this, because Glu33 from one Gal-10 monomer subunit occupies a large area in the ligand binding site of another subunit , such that lactose binding is inhibited. In the present study, we produced several single-site variants, with a focus on Glu33. The structure of E33A, with its shorter side chain, shows that this variant recovers the ability to bind lactose. In the hemagglutination assay, E33A is sensitive to lactose, whereas wild type Gal-10 is not. This indicates that lactose binding to E33A could abolish interactions between the ligands on erythrocytes and the lectin. Gel filtration profile of wild type Gal-10 and W127A. The elution peak of W127A indicates this variant is a monomer. However, Y35A still exists as a homodimer as proved by gel filtration (Supplementary Figure 3) .
Even though Gal-10 forms a novel dimeric structure , residues crucial to its dimerization had yet to be studied. For Gal-1, Cys2 and Val5 at the N-terminus are important for dimerization, such that their mutation abolishes dimer formation.
Recently, we also showed that two cysteines are important for Gal-13 dimerization . Here, we identified Trp127 as being key residue for Gal-10 dimerization. Although W127A is monomeric in solution, it crystallizes as a dimer, indicating that the crystallization pathway for W127A is same as wild type protein.
Interestingly, the hemagglutination assay shows that W127A has a higher biological activity than wild type Gal-10. This finding runs contrary to our expectation. We expected that this variant would have lower biological activity than the wild type lectin, because it forms monomers and not dimers. This may be explained by considering that the ligand binding site in W127A is more open and lacks the blocking Glu33 residues from another monomer subunit. Thus, it has a greater opportunity to bind ligands on the surface of erythrocytes. Although W127A is a monomer, it may be that changes on the erythorocyte surface induce hemagglutination. W127A also could bind to lactose-modified sepharose-6B, indicating that Gal-10 has a functional ligand binding site that can bind lactose. E33A could be co-crystallized with lactose, further confirming this view. Gal-10 mainly exists as a homodimer ). However, we could not exclude the possibility that Gal-10 homodimers disassociate into monomers in solution. Therefore, this dynamic process may regulate the physiological function and biological activity of Gal-10.
Gal-10, an abundant protein in eosinophils, can spontaneously form crystals in vivo (Ackerman et al. 1982; Calafat et al. 1997) . Electron microscopy shows that crystallized Gal-10 is distributed in the cytoplasm and nucleus of eosinophils and basophils (Calafat et al. 1997) . In eosinophils, Gal-10 is associated with specific granules, indicating that the CLC protein-containing granules are related to specific core-containing granules in eosinophils. In basophils, however, Gal-10 could be concentrated in the large granules that indicates Gal-8_1-186 , WT, E33A, E33D, E33Q, Y35A and W127A bind to lactose-modified sepharose-6B beads. An arrow indicates that W127A could bind to the beads. All other Gal-10 variants could not be recovered by the beads. W127A. E33D, E33Q, Y35A and W127A are extensively distributed in the euchromatin, but not in the heterochromatin. However, WT, E33A, H53A and N65A are equally distributed within the nucleus, indicating that Gal-10 may be in dynamic exchange in the nucleus. W72A is only distributed within the cytoplasm, either forming aggregates or entering granules.
contain histamine (Calafat et al. 1997 ). Electron microscopy also shows that Gal-10 is mainly localized in the euchromatin of the nucleus and not in heterochromatin (Calafat et al. 1997) . Here, our EGFP-tagged Gal-10 shows a similar cellular distribution as Calafat's study, indicating that esosinphils and HeLa cells have a similar transport system for Gal-10. This also implies that EGFP-tag did not influence the normal distribution of Gal-10 in cells. However, W72A could not enter the nucleus, indicating that it is a key residue for Gal-10 transport into the nucleus. In a previous report, wild type Gal-10 and W72A were co-crystallized with glycerol . However, the conformation of glycerol in W72A is quite different from that in wild type Gal-10. Moreover, W72A exhibits greater hemagglutination activity than wild type Gal-10. This in turn indicates that Trp72 is a key residue in determining Gal-10 ligand binding specificity. The ligand binding specificity of W72A must be different from wild type Gal-10; therefore, this variant could not be transferred into the nucleus via interactions with its transport partner compared to wild type Gal-10.
In conclusion, we report here on the Gal-10 ligand binding specificity, its key residue in homodimer formation, and its cellular distribution. We found that the ability of Gal-10 to bind lactose could be recovered by mutation of Glu33 to alanine. Trp127 was identified as being crucial for Gal-10 dimerization. Unlike wild type Gal-10, its variant W127A could bind to lactose-modified sepharose-6B, implying that the function of Gal-10 may be regulated by changing its oligomeric state. Finally, we reported on the cellular distribution of EGFP-tagged Gal-10 in HeLa cells, where its relatively broad distribution implies that this lectin likely has multiple cellular functions.
Materials and Methods
Site-directed mutagenesis and protein purification
The wild type Gal-10 over-expression plasmid was used as the template for site-directed mutagenesis. Site-directed mutagenesis of Gal-10 was performed according to the manual in the QuickChange XL site-directed mutagenesis kit (Stratagene, La Jolla, Canada). After site-directed mutagenesis, the sequences of all constructs were checked by DNA sequencing. The constructs were transformed into E. coli BL21 (DE3) cells and plated on LB agar plate supplemented with 100 μg/mL kanamycin. After overnight culture, E. coli BL21 (DE3) colonies were scraped from the LB agar plates and transferred into a 10 mL LB medium containing 100 μg/ mL kanamycin. The culture was shaken at 37°C, overnight. In the next day, all LB medium containing E. coli BL21 (DE3) cells were transferred into a 1 L LB medium and shaken at 37°C. When the optical density (OD600) of the cultures reached 1.2-1.5, IPTG was added to a final concentration of 0.5 mM to induce protein overexpression. After the induction, the cells were harvested by centrifugation (6000 ×g for 15 min) and lysed by sonification in a lysis buffer consisted of 10 mM Tris/HCl, pH 8.0, 300 mM NaCl, 2 mM β-mercaptoethanol, 20 mM imidazole. The clarified cell extract was used for protein purification with Ni-NTA Agarose (Qiagen, Hilden, Germany). After purification, the His-tagged protein was dialyzed in 10 mM Tris-HCl, pH 7.5; 150 mM NaCl; 2 mM β-mercaptoethanol. During dialysis, thrombin was added to remove the His tag with 10 units (National Institutes of Health unit) per milligram protein. As determined by SDS-PAGE, all protein purities were >90%. Proteins were concentrated to approximately 5 mg/mL and stored at −80°C.
Crystallization, data collection and structure determination
To obtain crystals suitable for X-ray diffraction, we optimized the crystals by using the conditions containing 0.1 M Bis-Tris pH 5.5, 1.6-2.2 M (NH 4 ) 2 SO 4 , with or without 10 mM lactose. Larger crystals were obtained after 1-7 days from drops that contained 1 μL protein and 1 μL solution from the well at 25°C. Prior to X-ray data collection, crystals were soaked in the reservoir solution supplemented with 20% (v/v) PEG400 as a cryoprotectant, and then flash cooled in liquid nitrogen. Data sets were collected at 100 K at the Shanghai Synchrotron Radiation Facility (Shanghai, China).
Data sets were indexed and integrated using XDS and scaled using Aimless from the CCP4 package (7.0.057, Science and Technology Facilities Council, Rutherford Appleton Laboratory, Didcot, Oxon, UK, 2015). Structures were determined by Phaser with a molecular replacement method using the structure of Gal-10 (PDB: 5XRH) as the search model. Structure refinement and water updating were performed using Phenix refine and manual adjustment. Final structure validations were performed using MolProbity.
Figures for all structures were generated using Chimera or Coot.
Gel filtration
Gel filtration was performed according to previous reported procedures with modification . A Superdex 75, 10/ 300 column was installed in the Äkta purifier 10 system (GE Healthcare, Uppsala, Sweden) and used to determine the elution volume of Gal-10 variants. Before sample loading, proteins were centrifuged at 12,000 × g for 5 min to remove tiny particles or precipitants. A total of 400-μg protein sample was loaded onto the column and eluted at a flow rate of 1 mL/min with a running buffer of PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na 2 HPO 4 , 10 mM KH 2 PO 4 , pH 7.4). The absorbance of proteins was monitored at 280 nm. Four standards proteins and one compound (bovine serum albumin (67.0 kDa), ovalbumin (43.0 kDa), ribonuclease A (13.7 kDa), aprotinin (6.5 kDa) and vitamin B12 (1.4 kDa)) were used to generate a standard curve for calculating Gal10 variants molecular weight. Thyroglobulin (669.0 kDa) was used to determine the void volume of the column.
Hemagglutination assay
The hemagglutination assay was performed according to published protocols Gao et al. 2013 ) with minor modifications. Chicken erythrocytes were prepared from fresh blood collected in Alsever's medium (2.05% glucose, 0.8% sodium citrate, 0.42% sodium chloride and 0.055% citric acid) and were washed four times with 0.15 M NaCl. Cells were then suspended in 4% (v/ v) PBS containing 1 mg/mL trypsin and incubated at 37°C for 1 h. After washing with 0.15 M NaCl, the cells were fixed for 1 h in PBS containing 1% glutaraldehyde at room temperature followed by termination with five volumes of 0.1 M glycine in PBS. The fixed cells were washed and adjusted to 10% (v/v) with PBS. Cells were maintained at 4°C until use. The hemagglutination assay was performed in microtiter V plates, with each well containing Gal-10 variants in 75 μL Tris buffer (10 mM Tris-HCl, 150 mM NaCl, pH 8.0) or 75 μL Tris buffer and 25 μL 4% (v/v) chicken erythrocyte suspensions. The cells were added last, followed by shaking, and agglutination was allowed to proceed for 60 min on the ice to ensure the temperature was consistent. Lactose and sucrose were used to inhibit the biological activity of Gal-10 variants.
Solid phase assay
The experiment was performed according to the published protocol (Fornstedt et al. 1975 ). Gal-10 variants (25 μg) or Gal-8_1-186 (25 μg) were added to 50 μL lactoseSepharose 6b beads. The solution was incubated in 1.5 mL microtubes with gentle stirring at 4°C for 2 h. Tubes were then centrifuged at 1000 × g for 1 min to sediment the agarose beads. The beads were washed by PBS for four times. Bound protein was eluted with 300 mM lactose, sequentially. Each supernatant was collected and prepared in loading buffer and heated to 98°C for 10 min prior to running SDS-PAGE. The protein bands were stained by commassie blue.
Transfection assay
Gal-10 variants were cloned into a EGFP-expressing vector pEGFP-N1 with two restriction sites (XhoI and HindIII). Before transfection, HeLa Cells was maintained in RPMI1640 growth medium supplemented with 10% newborn bovine serum and 100 units/mL of penicillin-streptomycin at 37°C in an atmosphere of 5% CO 2 /air. When the cell density reached about 70-80%, the complete medium was changed to RPMI1640 without serum. A volume of 3 μg of plasmid and 3 μg of PEI were diluted to 300 μL blank medium and mixed completely and incubated for 20 min at room temperature. The mixture of pEGFP-N1_Gal-10 with PEI was placed into the plates. After 6 h transfection, the medium was replaced with complete medium. Hoechst 33342 was used to stain the nucleus of HeLa cells. Before staining, the cells were washed by PBS for two times. Afterwards, the cells were fixed by 4% formaldehyde for 15 min at room temperature. Then, the cells were washed by PBS for two times. The nucleuses were stained in a 2 mL solution supplemented with 1 μg/mL of hoechst 33342 for 15 min. Afterwards, the fluorescences of EGFP and hoechst 33342 were determined and captured by a fluorescence microscopy (OLYMPUS, IX71).
Supplementary data
Supplementary data is available at Glycobiology online. 
